MONOVISC is a single high dose viscosupplement injection for the treatment of OA in the knee joint
- Highest concentration HA creates a high viscosity environment to replicate healthy joint function
- Optimal high-molecular-weight results in greater pain reduction and longer duration of effect
- Lightly cross-linked HA leads to longer residence time in joint and better viscoelasticity of synovial fluid
- Ultra pure non-avian HMW HA produced via bacterial fermentation – no adverse events reported and only a 2.5% rate of mild injection site reactions
- MONOVISC delivers a 65% improvement in WOMAC pain at week 26 relative to baseline (p =0.0352)
- High concentrate Hyaluronate Acid
- MONOVISC delivers an 85% responder rate in the OMERACT-OARSI Responder Index through 26 weeks
- MONOVISC patients experienced a clinically meaningful reduction in OA knee pain within two weeks of their injection
Helping 
